---
title: "Early feasibility study of TAVI platform for treatment of aortic regurgitation completes enrolment"
date: "2024-02-06T09:52:16.000Z"
publishedDate: "6 février 2024"
summary: "Genesis MedTech has announced the completion of enrolment in its US early feasibility study (EFS) using its dedicated transcatheter aortic valve implantation (TAVI) platform, the J-Valve transfemoral system. The US Food and Drug Administration (FDA) approved EFS trial involved patient enrolment at five centres across the USA."
importance: ""
sourceUrl: "https://cardiovascularnews.com/efs-j-valve-completes-enrolment/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-02-06-early-feasibility-study-of-tavi-platform-for-treatment-of-aortic-regurgitation-completes-enrolment"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2019/01/j-valve.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/efs-j-valve-completes-enrolment/"
---

![Early feasibility study of TAVI platform for treatment of aortic regurgitation completes enrolment](https://cardiovascularnews.com/wp-content/uploads/sites/14/2019/01/j-valve.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/efs-j-valve-completes-enrolment/*

## L’essentiel

Genesis MedTech has announced the completion of enrolment in its US early feasibility study (EFS) using its dedicated transcatheter aortic valve implantation (TAVI) platform, the J-Valve transfemoral system. The US Food and Drug Administration (FDA) approved EFS trial involved patient enrolment at five centres across the USA.

## Lien source

https://cardiovascularnews.com/efs-j-valve-completes-enrolment/
